Opioid Use Disorder and Opioid Agonist Treatment

0.0(0)
Studied by 1 person
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/35

encourage image

There's no tags or description

Looks like no tags are added yet.

36 Terms

1
New cards

Alberta apparent opioid toxicity deaths

Alberta is disproportionately affected by opioid deaths. Last year we had 1,145

2
New cards

Current unintentional acute drug poisoning deaths trend

Lowering, but still above pre-covid levels due to big changes in drug creation

3
New cards

Within alberta has the most opioid related overdoses

Edmonton

4
New cards

What percentage of individuals used a health care service within 30 days of a non-pharmaceutical opioid death?

53% (one of: antidepressants/antiolytic dispensed, ED visit, Opoiod dependency therapy)

5
New cards

Most common substances found involved in drug-induced death

Fentanyl ,Carfentanil, Methamphetamine

6
New cards

Most common liocations of unintentional opioid poisoning death

Personal residence, or public location

7
New cards

Risk of opioid related death after an ED visit

Mortality rate 3.5X higher for those who visited with an overdose related visit. Mortality 7.1X higher for those who left AMA

8
New cards

Timeline of opioid-related deaths following ED visit

Most deaths occured within 1 month of visit (20.5%)

9
New cards

Why are opioid related deaths so high following an ED visit?

Time spent in hospital can lower tolerance, meaning the first dose after being in the hospital has a higher risk of toxicity

10
New cards

Unintentional opoiod poisoning deaths in first natations people

Number of these deaths is is significantly higher epr capita in First nations people versus non-first nations people

11
New cards

DSM-5 diagnosis of opioid use disorder

Must fill out several criteria that include:

  • Taking more or for longer than intended

  • Repeated failed attemps to cut down or stop

  • Spending a lot of time obtaining, using, or recovering form use

  • Craving

  • Role failure (home, work, school obligations)

  • Persistant use despite relationship problems caused by it

  • Important activities given up or reduced by substance use

  • recurrent use in hazardous situations

  • Persistant use despite physical or psychological problems

  • Tolerance

  • Withdrawal symptoms


12
New cards

Opioud use disorder standard of care

Adults with opioid use disorder should have access to:

  • Opioid agonist treatment

  • Psychosocial supports

  • Safer use education

  • Safer use supplies

  • Take home naloxone kits


13
New cards

What drugs can be used in opioid agonist treatment (OAT)

Buprenorphine, methadone, slow-release oral morphine

14
New cards

What is Buprenorphine

  • High affinity, paetial agonist for the mu opioid receptor

  • Used in agonist treatment due to its ceiling effects for receptor mediated effects such as respiratory depression or euphoria


15
New cards

Buprenorphine

  • Slow dissociation kinetics (166 mins)

  • Half life 24-42 hours (transmucosal formulation)


16
New cards

Use of microinduction dosing of Suboxone (Buprenorphine/naloxone)

Used when patient needs to be on another opioid for pain. Then once the pain subsides you can switch purely over to Suboxone

17
New cards

Use of macro induction of Suboxone

Used when patient is in active withdrawal (used as a correction)

18
New cards

What is Subclocade

Buprenorphine extended release injection

Once monthly subcutaneous injection for patients stabilized on 8-24 mg of Suboxone for a minimum of 7 days

19
New cards

What is Methadone

  • Full agonist opioid with activity predominantly at the mu-opioid receptor

  • Some antagonist activity at the N-methyl-D-aspartate (NMDA)


20
New cards

Methadone kinetics

Peak plasma levels occur between 2.5-4 hours after ingestion


Variable elimination (22-48 hours) and takes time to reach steady state

21
New cards

Use of rapid titration of methadone

Used for individuals who have a higher tolerance

22
New cards

Methadone cautions

  • Multiple drug interactions

  • QTc prolongations

  • Increased risk of death during initiation and titration (first 2-4 weeks)

  • Narrow therapeutic index

  • Long elimination half life


23
New cards

OAT benefits on mortality

Rate of all cause mortality during OAT was halved. Lower risk for suicide, cancer, drug-related, and cardiovascular related mortality


No difference between methadone vs Buprenorphine

24
New cards

What is Kadian

Slow-release oral morpine

  • Full agonist opioid used for OAT when Methadone or Buprenorphine

  • Works similar to methadone in OAT


25
New cards

Kadian kinetics

Extensive but variable first pass metabolism, about 40% of the adiminstered dose reaches central component

Mean peak plasma concentration between 8.5-10 days. Steady state in about 2 days

26
New cards

Drawbacks of using slow release oral morphine for OAT

For patients with opioid use disorder, capsules are opened and ingestion must be witnessed in the pharmacy (must go to the pharmacy several times a day)

27
New cards

What is injectable opioid agonist treatment

High intensity treatment option for people with severe opioid use disorder where stabilixation has not occured with Methadone, Buprenorphine or oral morphine


Treatment is usually hydromorphone injection

28
New cards

Recovery oriented system of care for opioid use disorder

Counselling, peer supports, bed-based addiciton treatment. Collaborative approach, involve others as appropriate

29
New cards

Safety planning supports for opioid use disorder

Take home naloxone kit

Safer use education

New substance use equipment

Supervised consumption services

30
New cards

What is self stigma

  • Internalized negative messages about people who use drugs and apply them to themselves. It leads to low self esteem and feelings of shame


31
New cards

Effect of self stigma on opioid use disorder

Can cause someone to not access support because they fear being judged or discriminated against. This can cause someone to hide their drug use or use drugs alone

32
New cards

What is social stigma

Negative attitudes or behaviors towards people who use drugs or towards their friends or family members. Also includes negative labels in everydat conversation and in the media

33
New cards

What is structural stigma

Policies in health and social services that increase stigma, such as not providing services until drug use is better managed


Also includes workplace policies that cause harm and unintentionally encourage people hide their drug use to prevent them from seeking help

34
New cards

What are the 4 core issues found that help explaoni why people iwth substance use disorders leave the hospital prematurely

  1. Undertreated withdrawal and ongoing cravings

  2. Uncontrolled acute and chronic pain

  3. Stigma and discrimination

  4. Hospital retrictions


35
New cards

What is drug checking

Using paper spray MS to provide on-site drug checkig services at supervised consumption sites to allow users to know what is inside their drugs

36
New cards

What can helathcare workers do to improve treatment of opioid misuse/overuse?

  1. Be a safe person to talk to about substance use

  2. Educate yourself about substance use treatment and recovery

  3. Understand how to ID and respond to someone experiecining an opioid poisoning